Optimal timing and safety of non-vitamin K antagonist oral anticoagulant for atrial-fibrillation-related ischemic stroke
-
- Ugata Yusuke
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo
-
- Michihata Nobuaki
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo
-
- Matsui Hiroki
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo
-
- Fushimi Kiyohide
- Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine
-
- Yasunaga Hideo
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo
この論文をさがす
抄録
<p>BACKGROUND</p><p>In atrial-fibrillation (AF)-related acute ischemic stroke (AIS), the optimal timing for starting or resuming non-vitamin K antagonist oral anticoagulants (NOAC) remains unknown. We aimed to determine the optimal timing of NOAC initiation for AF-related AIS using the Japanese Diagnosis Procedure Combination inpatient database.</p><p>METHODS</p><p>We retrospectively collected data of adult inpatients who were admitted with a diagnosis of AF-related AIS from July 2010 to March 2016. Patients were divided into tertiles of hospital days for initiating NOAC (early, delayed, and late groups). Incidence of hemorrhagic events or NOAC discontinuation was the primary outcome. Secondary outcome included in-hospital death, any hemorrhagic event, thrombotic events, and deterioration of modified Rankin scale from admission to discharge. Logistic regression analyses were performed to compare the primary and secondary outcomes among the three groups with adjustments for patient backgrounds using inverse probability of treatment weighting by propensity score analysis.</p><p>RESULTS</p><p>We identified 55,289 eligible patients, including 17,810 in the early group (3–5 days), 18,473 in the delayed group (6–10 days), and 19,006 in the late group (≥11 days). Logistic regression analyses indicated the odds ratio for the primary outcome in the late group was not significant (adjusted odds ratio, 1.08; 95% confidence interval, 1.0–1.16).</p><p>CONCLUSIONS</p><p>NOAC initiation within 3–5 days was safer and associated with the lower proportions of the secondary outcomes in patients with AF-related AIS.</p>
収録刊行物
-
- Annals of Clinical Epidemiology
-
Annals of Clinical Epidemiology 2 (1), 3-12, 2020
一般社団法人 日本臨床疫学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390003825180869376
-
- NII論文ID
- 130007842638
-
- ISSN
- 24344338
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可